Google_______________

How Many Cases of Sexual HIV Transmission Occur during Acute Infection?

By Liz Highleyman

Experts believe that a substantial proportion of new HIV infections are transmitted by people who are themselves in the earliest stages of infection. Newly infected people tend to have high HIV viral loads -- a known risk factor for transmission -- and since they may not yet know they are infected, they may fail inform their sexual partners or employ safer sex precautions.

As reported in the July 31, 2007 issue of AIDS, Steven Pinkerton, PhD, of the Center for AIDS Intervention Research at the Medical College of Wisconsin designed a mathematical model to estimate the number of persons in the U.S. who acquire HIV as a consequence of high-risk sexual activities with an acutely infected partner.

Estimates of the number of incident infections due to transmission during the acute phase of infection were derived from a simple mathematical model that combined epidemiological data with information regarding the relative transmission rates for 3 groups:

Acutely infected individuals;

Individuals with non-acute (chronic) infection who are unaware of their serostatus;

Individuals who do not know their serostatus.

Results

The model suggested that approximately 2760 (8.6%) of the estimated 32,000 sexually acquired HIV infections in the U.S. each year are due to transmission during the acute phase of infection.

Multivariate sensitivity analyses with a liberal range of values for key parameters produced an upper bound of 5537 infections, representing 17.3% of all sexually acquired infections.

Conclusion

In conclusion, Pinkerton wrote, "Acute-phase HIV transmission accounts for fewer sexually-acquired infections in the USA than is generally assumed."

8/21/07

Reference
SD Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 21(12): 1625-1629. July 31, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)